Stealth cites endpoints in Phase III mitochondrial disease miss

Shares of Stealth BioTherapeutics sank 65% to $4.75 on Friday after the company announced a Phase III miss for its lead mitochondria-targeted therapy in primary mitochondrial myopathy, just two months after Alexion obtained an option to the candidate for

Read the full 392 word article

How to gain access

Continue reading with a
two-week free trial.